Key result
ACE I/D polymorphism is linked to COVID-19 severity but not overall infection susceptibility.
Meta-Analysis (n=4,590)
Effect estimate: OR (95% CI 0.5291-0.8353) (95% CI 0.5291-0.8353)
p-value: p=<0.001
Self-Correction*: The prompt says "complementary to the key finding above".
1] Recent advances in ... [2] A rapid and specific assay ... [3] SARS and MERS ... [4] A novel coronavirus ... [5] A pneumonia outbreak ... [6] Understanding the renin-angiotensin ... [7] High affinity binding of ... [8] Angiotensin converting ... [9] Focus on receptors ... [10] Human Ace D/I polymorphism ... [11] Association between angiotensinogen ... [12] Impact of I/D polymorphism ... [13] ACE I/D polymorphism ... [14] Preferred reporting ... [15] MetaGenyo: A web ... [16] Clinical Features ... [17] Risks of and risk factors ... [18] Angiotensin-converting ... [19] The pathogenicity ... [20] ACE2, angiotensin-(1-7) ... [21] The role of biomarkers ... [22] Clinical and biochemical ... [23] Angiotensin-converting ... [24] ACE gene I/D polymorphism ... [25] Association between ... [26] Ethnic and age-specific ... [27] Angiotensin-converting ... [28] ACE deletion ... [29] ACE gene I/D polymorphism ...
No takes yet. Share an insight, caveat, or question.
Nikooe et al. (2022) conducted a meta-analysis in COVID-19 (n=4,590). ACE I/D polymorphism vs. Alternative ACE genotypes/alleles was evaluated on Severity of COVID-19 infection (allele contrast I vs. D) (OR (95% CI 0.5291-0.8353), 95% CI 0.5291-0.8353, p=<0.001). The ACE I/D polymorphism was significantly associated with the severity of COVID-19 infection in the allele contrast model, but showed no association with COVID-19 susceptibility.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: